-
Qilu Pharmaceutical's new pancreatic cancer drug was approved for clinical use
Time of Update: 2021-08-05
The Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China has announced that the CEND-1 for injection introduced by Qilu Pharmaceutical has obtained an implied license for a clinical trial and is intended to be developed for the first-line treatment of advanced metastatic pancreatic cancer .
-
Sanofi announces Dupixent's 10 billion goal of chronic spontaneous urticaria may be achieved
Time of Update: 2021-08-05
Sibold said in a conference call on Thursday that Dupixent currently has annual sales of 5 billion euros .
The vaccine business generated 1 billion euros in revenue during the quarter, an increase of 16% .
-
Hengrui Medicine Propofol Medium/Long Chain Fat Emulsion Injection Obtained Drug Registration Certificate
Time of Update: 2021-08-05
Propofol medium/long-chain fat emulsion injection is a fast-acting short-acting general intravenous anesthetic.
In February 2007, Fresenius Kabi’s Propofol Medium-Long/Chain Fat Emulsion Injection was approved for listing in China .
-
The GlaxoSmithKline shingles vaccine Shingrix received a key US FDA approval!
Time of Update: 2021-08-05
In the European Union, Shingrix was approved in August 2020 for adults aged 18 and over who are at increased risk of shingles, 11 months ahead of the US FDA’s approval, but the COVID-19 pandemic disrupted the rollout plan.
-
New developments in potential "specific drugs" for new crowns: masitinib+S2H97
Time of Update: 2021-08-05
How to deal with the continuous evolution of the new coronavirus and develop neutralizing antibodies or new coronavirus vaccines that have a "broad-spectrum effect" and prevent the virus from escaping are important issues that researchers need to solve .
-
IND application for CD47/Her2 double antibody project was accepted by FDA
Time of Update: 2021-08-05
On July 28, ImmuneOnco announced that the world's first dual-target antibody-receptor recombinant protein drug targeting human CD47 x Her2 (IMM2902) has been accepted by the US FDA for a new drug clinical research application (IND) .
-
A batch of pharmacy window advertisements are banned
Time of Update: 2021-08-05
It is understood that the Municipal Urban Management and Law Enforcement Bureau conducted a comprehensive survey of pharmacies in the central city, interviewed the heads of more than 50 chain enterprises in 453 pharmacies, urged themselves to clean up the indiscriminately posted advertisements in the stores, and signed a letter of commitment.
-
To ensure that the three-child policy is effective, the National Health Commission puts forward six key tasks
Time of Update: 2021-08-05
Standard Standard Standard care health care Regarding the development of childcare services, the notice proposes to study and formulate a special plan for the development of childcare services during the 14th Five-Year Plan; implement the “14th Five-Year” public childcare service capacity building project and special actions for inclusive childcare services, and expand investment within the central budget , Support social forces to develop community nursery service facilities and comprehensive nursery service institutions .
-
AstraZeneca/Daiichi Sankyo declares TROP 2 ADC
Time of Update: 2021-08-05
The development of DS-1062a for NSCLC is currently in phase III clinical phase, and a new phase I cohort study for HR+/HER2- breast cancer patients has also been opened .
-
Borui Pharmaceuticals "Oseltamivir Capsules" Approved for Listing
Time of Update: 2021-08-05
Currently, according to the Insight database, Dongyang Sunshine has two dosage forms of oseltamivir capsules and granules, and has also submitted an application for the marketing of oseltamivir dry suspension, which is currently under review and approval; at the same time, it has also applied for sustained-release tablets.
-
Sino-US double batch!
Time of Update: 2021-08-05
On July 27, Hengrui Medicine announced that its self-developed long-acting insulin/GLP-1 analog fixed-ratio compound preparation HR17031 injection has been approved for clinical use in China and is intended to be used for the treatment of type 2 diabetes .
-
The State Food and Drug Administration released a catalog of generic drug reference preparations
Time of Update: 2021-08-05
After review and determination by the Expert Committee of the Quality and Efficacy Consistency Evaluation of Generic Drugs of the National Medical Products Administration, the catalogue of generic drug reference preparations (the 43rd batch) is now released .
Attachment: List of Generic Drug Reference Preparations (Forty-third batch)
-
Hong Kong and Macau health officials talk about the development of Chinese medicine: strengthening cooperation and exchanges to promote inheritance and innovation
Time of Update: 2021-08-05
At the 2021 Shanghai Cooperation Organization Traditional Medicine Forum plenary meeting held on the afternoon of the 29th, two health officials from Hong Kong and Macau shared their experience in the development of Chinese medicine .
-
The price of heavy and large varieties is reduced by more than 50%
Time of Update: 2021-08-05
On the same day, the Centralized Procurement Network of Medicines and Medical Consumables in Liaoning Province issued the "Notice on the Implementation of the Results of Active Price Reduction of Two Drugs including Dalley Tuumab Injection .
-
Pien Tze Huang's collaborative research and development project LDS tablets for the treatment of fibromyalgia was approved for clinical use
Time of Update: 2021-08-05
On July 27, Pien Tze Huang issued an announcement stating that LDS tablets, a research and development project in cooperation with Lidao Pharmaceutical, received the "Notice of Drug Clinical Trial Approval" issued by the State Drug Administration .
-
The Qinghai Sea line medical insurance information platform helps solve the problem of "errands and time-consuming"
Time of Update: 2021-08-05
The relevant person in charge of the Qinghai Provincial Medical Security Bureau said that after the platform is launched, it will create more efficient, convenient, high-quality and safe medical insurance public service conditions for more than 5.
-
Production shrinks, imports are blocked, and turmeric prices rise!
Time of Update: 2021-08-05
In recent years, due to the impact of foreign low-priced goods, the domestic authentic variety Chuan turmeric has suffered from low prices and shrinking planting areas, which has attracted market attention .
-
Sichuan pharmaceutical companies are showing off!
Time of Update: 2021-08-05
Recently, the good news of Better Pharmaceutical’s product line has continued: Cefmetazole Sodium for Injection was the first to have been evaluated, the first class new drug BT-101094 capsule was approved for clinical use, and it has reached a cooperation with Guangzhou Kangchen in the field of contrast agents .
-
Nuocheng Jianhua SHP2 allosteric inhibitor submits clinical application
Time of Update: 2021-08-05
According to the press release, ICP-189 is mainly used to treat a variety of solid tumors.
It aims to provide new solid tumors such as lung cancer, head and neck cancer and gastrointestinal tumors Clinical treatment methods .
-
BMS withdraws Opdivo monotherapy for sorafenib treatment failure indication for hepatocellular carcinoma
Time of Update: 2021-08-05
However, in the confirmatory clinical trial CheckMate-459, Opdivo and Sorafenib head-to-head first-line treatment of patients with hepatocellular carcinoma in the pre-specified analysis, the primary endpoint of overall survival did not reach statistical significance .
